Product Reports Resources Pricing Login Book a demo

Zealand Pharma

Biotech & Life Sciences · Søborg, Denmark · Founded 1998 · IPO 2017

Discovery, design and development of innovative peptide-based medicines

Valuation $1.61B
Revenue $679M
EBITDA $213M

Talent graph

Zealand Pharma's talent

Book a demo to see the people
Employees mapped 618 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 16 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 6 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Zealand Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Series B+ 4 investors entered at this stage
Van Herk Investments
Sanofi-Genzyme BioVentures
Kurma Partners
HBM Healthcare Investments

Ownership

Who owns Zealand Pharma

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (2026).

7.5% Van Herk Investments B.V.

“Other / undisclosed” is the 72.5% not attributed to a named shareholder. See the full cap table on Dealroom →

Global footprint

Where Zealand Pharma has talent and traffic

Workforce by country
6 countries with
team presence
🇩🇰 Denmark90.8%
🇺🇸 United States6.4%
🇸🇪 Sweden1.8%
🇫🇷 France0.5%
🇨🇭 Switzerland0.3%
Top 5 of 6 shown
Web traffic by country
21K monthly visits
across markets
🇺🇸 United States26.7%
🇩🇰 Denmark26.2%
🇮🇳 India11.4%
🇬🇧 United Kingdom10.5%
🇫🇷 France8.6%
Top 5 markets shown

Patent intelligence

$240M patent portfolio · 117 active families

Estimated portfolio value
$240M
14.9% of market cap · 3.3× smaller than top peer BioNTech ($788M)
117 active patent families
Where Zealand Pharma innovates Biomedical engineeringAgonistAmbulatoryBody weightControl system

Where Zealand Pharma concentrates vs peers

Each axis is a top-10 topic across Zealand Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Zealand Pharma's 3 investments and acquisitions.

Every disclosed deal where Zealand Pharma appeared as a backer or acquirer, 2019–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Zealand Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Zealand Pharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Zealand Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Zealand Pharma

        An AI-synthesized read of the highest-engagement posts about Zealand Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Zealand Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.